Physical interaction of the retinoblastoma protein with human D cyclins

doi:10.1016/0092-8674(93)90137-F

Cell

Volume 73, Issue 3, 7 May 1993, Pages 499-511

https://doi.org/10.1016/0092-8674(93)90137-F Get rights and content

Abstract

The retinoblastoma protein (pRb) functions as a regulator of cell proliferation and in turn is regulated by cyclin-dependent kinases. Cyclins D1 and D3 can form complexes with pRb that resemble those formed by several viral oncoproteins and are disrupted by the adenovirus E1A oncoprotein and derived peptides. These cyclins contain a sequence motif similar to the pRb-binding conserved region II motif of the viral oncoproteins. Alteration of this motif in cyclin D1 prevents formation of cyclin D1-pRb complexes while enhancing the biological activity of cyclin D1 assayed in vivo. We conclude that cyclins D1 and D3 interact with pRb in a fashion distinct from cyclins A and E, which can induce pRb hyperphosphorylation, and that cyclin D1 activity may be regulated by its association with pRb.

References (95)

K. Buchkovich et al.
The retinoblastoma protein is phosphorylated during specific phases of the cell cycle
Cell
(1989)
F. Chang et al.
Identification of a gene necessary for cell cycle arrest by a negative growth factor of yeast: FAR1 is an inhibitor of a G1 cyclin, CLN2
Cell
(1990)
S.P. Chellappan et al.
The E2F transcription factor is a cellular target for the RB protein
Cell
(1991)
P.-L. Chen et al.
Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation
Cell
(1989)
T. Chittenden et al.
The $T E1A - binding$ domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein
Cell
(1991)
J.A. DeCaprio et al.
SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene
Cell
(1988)
J.A. DeCaprio et al.
The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element
Cell
(1989)
M.E. Ewen et al.
Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein
Cell
(1991)
D.W. Goodrich et al.
The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle
Cell
(1991)
W. Gu et al.
Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation
Cell
(1993)

K. Helin et al.

A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F

Cell

(1992)

P.W. Hinds et al.

Regulation of retinoblastoma protein functions by ectopic expression of human cyclins

Cell

(1992)

T. Hunt

Maturation promoting factor, cyclin and the control of M-phase

Curr. Opin. Cell Biol.

(1989)

T. Hunter et al.

Cyclins and cancer

Cell

(1991)

T. Inaba et al.

Genomic organization, chromosomal localization, and independent expression of human cyclin D genes

Genomics

(1992)

W.G. Kaelin et al.

Identification of cellular proteins that can interact specifically with the $T E1A - binding$ region of the retinoblastoma gene product

Cell

(1991)

W.G. Kaelin et al.

Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties

Cell

(1992)

A. Koff et al.

Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family

Cell

(1991)

D.J. Lew et al.

Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast

Cell

(1991)

J.W. Lillie et al.

Functional domains of adenovirus type 5 E1a proteins

Cell

(1987)

J.W. Ludlow et al.

SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family

Cell

(1989)

H. Matsushime et al.

Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle

Cell

(1991)

H. Matsushime et al.

Identification and properties of an atypical catalytic subunit (p34^PSK-J3/cdk4) for mammalian D type G1 cyclins

Cell

(1992)

S. Mittnacht et al.

$G1 S$ phosphorylation of the retinoblastoma protein is associated with an altered affinity for the nuclear compartment

Cell

(1991)

T. Motokura et al.

Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene

J. Biol. Chem.

(1992)

S.I. Reed

G1 specific cyclins: in search of an S-phase promoting factor

Trends Genet.

(1991)

G. Shaw et al.

A conserved AU sequence from the 3′ untranslated of GM-CSF mRNA mediates selective mRNA degradation

Cell

(1986)

S. Shirodkar et al.

The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner

Cell

(1992)

P. Whyte et al.

Cellular targets for transformation by the adenovirus E1A proteins

Cell

(1989)

Y. Xiong et al.

Human D-type cyclin

Cell

(1991)

Y. Xiong et al.

Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins

Genomics

(1992)

Y. Xiong et al.

D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA

Cell

(1992)

L.R. Bandara et al.

Adenovirus E1A prevents the retinoblastoma gene product from complexing with a cellular transcription factor

Nature

(1991)

C. Chen et al.

High-efficiency transformation of mammalian cells by plasmid DNA

Mol. Cell. Biol.

(1987)

V. Cherington et al.

Separation of simian virus 40 large-T-antigen-transforming and origin-binding functions from the ability to block differentiation

Mol. Cell. Biol.

(1988)

J.A. DeCaprio et al.

The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression

D. Defeo-Jones et al.

Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product

Nature

(1991)

V. Dulić et al.

Association of human cyclin E with a periodic G1-S phase protein kinase

Science

(1992)

N. Dyson et al.

The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product

Science

(1989)

N. Dyson et al.

Adenovirus E1A makes two distinct contacts with the retinoblastoma protein

J. Virol.

(1992)

M.E. Ewen et al.

Functional interactions of the retinoblastoma protein with mammalian D-type cyclins

Cell

(1993)

J. Figge et al.

Prediction of similar transforming regions in simian virus 40 large T, adenovirus E1A, and Myc oncoproteins

J. Virol.

(1988)

S.H. Friend et al.

Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein

Y. Furukawa et al.

Heterogenous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells

Oncogene

(1991)

J.W. Harbour et al.

Abnormalities in structure and expression of the human retinoblastoma gene in SCLC

Science

(1988)

E. Harlow et al.

Association of adenovirus early-region 1A proteins with cellular polypeptides

Mol. Cell. Biol.

(1987)

P.W. Hinds et al.

Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes

Cell Growth Differ.

(1990)

Cited by (765)

Targeting Wnt/β-catenin signaling pathway in triple-negative breast cancer by benzylic organotrisulfides: Contribution of the released hydrogen sulfide towards potent anti-cancer activity
2022, Free Radical Biology and Medicine
The potent anti-cancer activity of naturally occurring organopolysulfides has attracted wide research attention over the last two decades. Sustained donation of hydrogen sulfide (H₂S) from organopolysulfides is found to be beneficial for the treatment of several organ-specific cancers. In the present study, for the first time, the mechanism of action for the potent anti-cancer activity of bis(3,5-dimethoxybenzyl) trisulfide 4 against highly aggressive triple-negative breast cancer cells (MDA-MB-231) is described. Preliminary in vitro studies revealed potent anti-proliferative activity of the trisulfide 4 against triple-negative breast cancer cells with an IC₅₀ value of 1.0 μM. Mechanistic studies reveal that the compound exhibited anti-cancer activity, primarily by targeting and suppressing the Wnt/β-catenin signaling pathway. The inactivation of the β-catenin level was associated with the cell cycle arrest in the G2/M phase and the significant down-regulation of downstream signaling genes such as Cyclin D1 and c-Myc expression. Several control experiments with analogous organosulfur compounds and the key enzyme inhibitors reveal that the presence of a trisulfide unit in the compound is crucial for the desired inactivation of β-catenin expression, which is promoted by GSK-3β-induced phosphorylation of β-catenin and its proteasomal degradation. Moreover, the trisulfide unit or the released H₂S induced down-regulation of the p53 expression with the possible S-sulfhydration process led to p53-independent up-regulation of p21 expression. Therefore, the key results of this study highlighting the potency of synthetic benzylic organotrisulfide and the released H₂S towards the growth inhibition of triple-negative breast cancer via Wnt/β-catenin signaling pathway would certainly be helpful for further studies and developing small-molecule anti-cancer therapeutics in future.
Leukemias, Lymphomas, and Plasma Cell Disorders
2022, Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics: Hematologic, Renal, and Immunologic Disorders
Leukemias, lymphomas, plasma cell disorders, and related neoplasms are hematologic malignancies characterized by various recurrent acquired genetic and genomic abnormalities. Identification of these anomalies can assist in diagnosis, therapeutic choice, risk assessment, prognosis, and disease monitoring. Conventional cytogenetics (karyotyping), fluorescence in situ hybridization, single-nucleotide polymorphism, chromosomal microarray, single-gene mutational assays, and next-generation sequencing/massively parallel sequencing (NGS/MPS) are techniques used to detect disease-related genomic aberrations, including genomic imbalances, gene mutations, fusion genes, and other chromosomal rearrangements. Each of these techniques has advantages and limitations, thus choosing the appropriate testing is dependent on the disease state, tissue source, suspected type of abnormality, and turnaround time to assure results in a clinically useful timeframe. Additionally, germline variants associated with predisposition to hematological malignancies have been identified in the pediatric and adult populations, with significant differences in age of presentation compared with cancers arising from mutations in traditional cancer predisposition genes.
The identification of the Philadelphia chromosome in chronic myeloid leukemia (CML) demonstrated the first direct evidence that cancer is a genetic disease (Nowell and Hungerford, 1960) and serves as a model for rational, molecularly targeted therapy. The Philadelphia chromosome was later shown to be a translocation involving chromosomes 9 and 22 (Rowley, 1973), demonstrating that nonrandom chromosomal rearrangements were associated with malignancy. The discovery that the t(9;22) leads to a novel fusion gene, BCR::ABL1, with a dysregulated a tyrosine kinase opened the door for development of a highly specific ABL1 inhibitor, imatinib. More recent studies have shown that some CML patients in a deep molecular response can be cured of their cancer through use of targeted therapy (reviewed in (Braun et al., 2020)). Many more genetic and genomic alterations have been identified in hematological malignancies that affect a variety of pathways using conventional cytogenetics and broad genomic sequencing, leading to more targeted and personalized therapies available. This chapter will focus on the cytogenetic and molecular alterations known to be associated with various hematologic malignancies and how detection of different disease associated mutations can be used for diagnosis, prognosis, risk assessment, and treatment.
Unraveling the links between neurodegeneration and Epstein-Barr virus-mediated cell cycle dysregulation
2022, Current Research in Neurobiology
The Epstein-Barr virus is a well-known cell cycle modulator. To establish successful infection in the host, EBV alters the cell cycle at multiple steps via antigens such as EBNAs, LMPs, and certain other EBV-encoded transcripts. Interestingly, several recent studies have indicated the possibility of EBV's neurotrophic potential. However, the effects and outcomes of EBV infection in the CNS are under-explored. Additionally, more and more epidemiological evidence implicates the cell-cycle dysregulation in neurodegeneration. Numerous hypotheses which describe the triggers that force post-mitotic neurons to re-enter the cell cycle are prevalent. Apart from the known genetic and epigenetic factors responsible, several reports have shown the association of microbial infections with neurodegenerative pathology. Although, studies implicating the herpesvirus family members in neurodegeneration exist, the involvement of Epstein-Barr virus (EBV), in particular, is under-evaluated. Interestingly, a few clinical studies have reported patients of AD or PD to be seropositive for EBV. Based on the findings mentioned above, in this review, we propose that EBV infection in neurons could drive it towards neurodegeneration through dysregulation of cell-cycle events and induction of apoptosis.
LxCxD motif of the APC/C coactivator subunit FZR1 is critical for interaction with the retinoblastoma protein
2021, Experimental Cell Research
Retinoblastoma protein (pRB) regulates cell cycle by utilizing different regions of its pocket domain for interacting with E2F family of transcription factors and with cellular and viral proteins containing an LxCxE motif. An LxCxE-like motif, LxCxD, is present in FZR1, an adaptor protein of the multi-subunit E3 ligase complex anaphase-promoting complex/cyclosome (APC/C). The APC/C^FZR1 complex regulates the timely degradation of multiple cell cycle proteins for mitotic exit and maintains G1 state. We report that FZR1 interacts with pRB via its LxCxD motif. By using point mutations, we found that the cysteine residue in the FZR1 LxCxD motif is critical for direct interaction with pRb. The direct binding of the LxCxD motif of FZR1 to the pRB LxCxE binding pocket is confirmed by using human papillomavirus protein E7 as a competitor, both in vitro and in vivo. While mutation of the cysteine residue significantly disrupts FZR1 interaction with pRB, this motif does not affect FZR1 and core APC/C association. Expression of the FZR1 point mutant results in accumulation of S-phase kinase-associated protein 2 (SKP2) and Polo-like kinase 1 (PLK1), while p27^Kip1 and p21^Cip1 proteins are downregulated, indicating a G1 cell cycle defect. Consistently, cells containing point mutant FZR1 enter the S phase prematurely. Together our results suggest that the LxCxD motif of FZR1 is a critical determinant for the interaction between FZR1 and pRB and is important for G1 restriction.
Investigation of the newly characterized baimantuoluoamide a and baimantuoluoamide b alkaloids as potential cyclin-dependent kinase 4 (CDK4) inhibitors using molecular docking and molecular dynamics simulations
2021, Journal of Molecular Structure
CDK4 is an enzyme often associated with various forms of cancer. Since an abnormal function of the CDK4-cyclin D1 protein complex can play a pivotal role in causing various types of cancer, CDK4 is considered an important therapeutic target. Traditionally, herbal medicines have played a vital role in the treatment of many diseases and ailments. Likewise, D. stramonium, Solanaceae, possesses the cytotoxic, anti-inflammatory, anti-viral, antibacterial, antioxidant, analgesic, antiulcer, and insecticidal properties which are a result of its phytoconstituents. Baimantuoluoamide A and baimantuoluoamide B are newly isolated Datura metel L. phytoconstituents, whose molecular interactions are still unknown. Additionally, an experimentally determined crystal structure of baimantuoluoamide A and baimantuoluoamide B bound to CDK4 has not yet been reported. Thus, this study aimed to identify the residues in the baimantuoluoamide A and baimantuoluoamide B-CDK4 binding interface. For this purpose, molecular docking, molecular dynamics (MD) simulations and the MM/GBSA method to identify the binding modes and crucial residues were employed. The results obtained in the current study will provide valuable guidelines for developing novel potent and selective CDK4 inhibitors.
Proline-Rich Motifs Control G2-CDK Target Phosphorylation and Priming an Anchoring Protein for Polo Kinase Localization
2020, Cell Reports
The hydrophobic patch (hp), a docking pocket on cyclins of CDKs (cyclin-dependent kinases), has been thought to accommodate a single short linear motif (SLiM), the “RxL or Cy” docking motif. Here we show that hp can bind different motifs with high specificity. We identify a PxxPxF motif that is necessary for G2-cyclin Clb3 function in S. cerevisiae, and that mediates Clb3-Cdk1 phosphorylation of Ypr174c (proposed name: Cdc5 SPB anchor-Csa1) to regulate the localization of Polo kinase Cdc5. Similar motifs exist in other Clb3-Cdk1 targets. Our work completes the set of docking specificities for the four major cyclins: LP, RxL, PxxPxF, and LxF motifs for G1-, S-, G2-, and M-phase cyclins, respectively. Further, we show that variations in motifs can change their specificity for human cyclins. This diversity could provide complexity for the encoding of CDK thresholds to achieve ordered cell-cycle phosphorylation.

View all citing articles on Scopus

View full text

Cell

ArticlePhysical interaction of the retinoblastoma protein with human D cyclins

Abstract

Cell

Cell

Cell

Cell

Cell

Cell

Cell

Cell

Cell

Cell

Cell

Cell

Curr. Opin. Cell Biol.

Cell

Genomics

Cell

Cell

Cell

Cell

Cell

Cell

Cell

Cell

Cell

J. Biol. Chem.

Trends Genet.

Cell

Cell

Cell

Cell

Genomics

Cell

Adenovirus E1A prevents the retinoblastoma gene product from complexing with a cellular transcription factor

Nature

High-efficiency transformation of mammalian cells by plasmid DNA

Mol. Cell. Biol.

Separation of simian virus 40 large-T-antigen-transforming and origin-binding functions from the ability to block differentiation

Mol. Cell. Biol.

The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression

Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product

Nature

Association of human cyclin E with a periodic G1-S phase protein kinase

Science

The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product

Science

Adenovirus E1A makes two distinct contacts with the retinoblastoma protein

J. Virol.

Functional interactions of the retinoblastoma protein with mammalian D-type cyclins

Cell

Prediction of similar transforming regions in simian virus 40 large T, adenovirus E1A, and Myc oncoproteins

J. Virol.

Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein

Heterogenous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells

Oncogene

Abnormalities in structure and expression of the human retinoblastoma gene in SCLC

Science

Association of adenovirus early-region 1A proteins with cellular polypeptides

Mol. Cell. Biol.

Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes

Cell Growth Differ.

Article
Physical interaction of the retinoblastoma protein with human D cyclins